ÆÆ¾ÖÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆÐ§ÏÔÖø-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬ £¬£¬£¬ÂȵªÆ½"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬ £¬£¬£¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£»£»£»£»£»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬ £¬£¬£¬ÂȵªÆ½"/> ÆÆ¾ÖÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆÐ§ÏÔÖø-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬ £¬£¬£¬ÂȵªÆ½"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬ £¬£¬£¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£»£»£»£»£»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"/>

½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ÆÆ¾ÖÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆÐ§ÏÔÖø

ÈÕÆÚ£º

2026Äê06ÔÂ15ÈÕ 15:43


ÌÇÄò²¡Éö²¡ÊÇʲô£¿£¿£¿£¿£¿£¿ £¿

 

ÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¨diabetic nephropathy£¬£¬£¬£¬ £¬£¬£¬DN£©ÊÇÌÇÄò²¡×îÑÏÖØºÍ×î³£¼ûµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬£¬£¬£¬ £¬£¬£¬ÔÚҽѧÉÏÒ²³ÆÎªÌÇÄò²¡ÉöСÇòÓ²»¯Ö¢¡£¡£¡£¡£¡£¡£ËüÊÇÂýÐÔÉöÔಡ£¡£¡£¡£¡£¡£¨chronic kidney disease£¬£¬£¬£¬ £¬£¬£¬CKD£©ºÍÖÕÄ©ÆÚÉöÔಡ£¡£¡£¡£¡£¡£¨end stage renal disease, ESRD£©µÄÖ÷Òª²¡Òò1¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬ £¬£¬£¬ÔÚÎÒ¹úÒÔÖÂÈ«ÇòÌÇÄò²¡Éö²¡·¢²¡Âʾù³ÊÉÏÉýÇ÷ÊÆ¡£¡£¡£¡£¡£¡£

ÌÇÄò²¡Éö²¡ÊÇÓÉÓÚºã¾Ã¸ßѪÌÇ״̬µ¼ÖÂÉöÔà½á¹¹ºÍ¹¦Ð§Öð½¥ÊÜËðµÄ²¡ÀíÀú³Ì¡£¡£¡£¡£¡£¡£»£»£»£»£»¼Õß»úÌå±£´æ¼«ÆäÖØ´óµÄ´úлÔÓÂÒ£¬£¬£¬£¬ £¬£¬£¬Ò»µ©Éú³¤µ½ÖÕÄ©½×¶Î£¬£¬£¬£¬ £¬£¬£¬ÍùÍù±ÈÆäËûÉöÔ༲²¡ÖÎÁÆÔ½·¢¼¬ÊÖ¡£¡£¡£¡£¡£¡£ÌÇÄò²¡Éö²¡ÔçÆÚÌØÕ÷ÐԸıä°üÀ¨ÉöСÇòÂ˹ýÂÊÔö¸ß¡¢ÉöÌå»ýÔö´ó£¬£¬£¬£¬ £¬£¬£¬Ëæºó·ºÆð΢Á¿°×ÂѰ×Äò£¬£¬£¬£¬ £¬£¬£¬¼Ì¶øÉú³¤ÎªÁÙ´²ÂѰ×Äò¡¢ÉöÏËά»¯£¬£¬£¬£¬ £¬£¬£¬×îÖÕµ¼ÖÂÉö¹¦Ð§¾ÙÐÐÐÔϽµ£¬£¬£¬£¬ £¬£¬£¬Ö±ÖÁÖÕÄ©ÆÚÉöË¥½ß1¡£¡£¡£¡£¡£¡£

£¨Í¼Æ¬ÈªÔ´£ºhttps://www.hjtdsm.com/yiyong/dn£©

 

¼òÎöÏÖÓÐÁÆ·¨£¬£¬£¬£¬ £¬£¬£¬¿ÉÒÔ·¢Ã÷£¬£¬£¬£¬ £¬£¬£¬È±·¦Äܹ»Ö±½Ó¡¢Ç¿Á¦×è¶ÏÉöÔàÄÚÔÚÑ×Ö¢ºÍÏËά»¯Àú³ÌµÄ¶à°ÐµãÒ©Î£¬£¬£¬ £¬£¬£¬ÊÇÄ¿½ñÌÇÄò²¡Éö²¡ÖÎÁÆÁìÓò×îÖ÷ÒªµÄÁÙ´²Î´Öª×ãÐèÇ󡣡£¡£¡£¡£¡£

½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú£¨ÒÔϼò³Æ“½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú”£©×ÔÖ÷Ñз¢µÄС·Ö×Ó»·ëÄ£¨MCR¶àëÄ£©ÔÚ×Ô¾õÐÍÌÇÄò²¡Éö²¡Ä£×ÓСÊó——db/dbСÊóÉÏÈ¡µÃÁËÏÔÖøÁÆÐ§£¬£¬£¬£¬ £¬£¬£¬Í¨¹ý¶à°ÐµãЭͬÔöЧ£¬£¬£¬£¬ £¬£¬£¬ÓÐÍû´øÀ´DNµÄÁÙ´²ÐÂÑ¡Ôñ£¡

 

MCR»·ëÄÁÆÐ§ÏÔÖø

 

db/dbСÊóÊÇÑо¿ÔçÆÚÌÇÄò²¡Éö²¡²¡±äµÄ³£ÓÃÄ£×Ó£¬£¬£¬£¬ £¬£¬£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ£¬£¬£¬£¬ £¬£¬£¬³ýÁ˻᷺Æð·ÊÅÖ¡¢¸ßѪÌǵÈÖ¢×´£¬£¬£¬£¬ £¬£¬£¬¸ÃÄ£×ÓСÊóͨ³£»£»£»£»£»¹ÔÚÉúÃüÔçÆÚÌåÏÖ³öÏÔ×ŵÄÉöСÇòËðÉË£¨·Ê´ó¡¢Ï¸°ûÔö¶àºÍÉöСÇòÓ²»¯£©£¬£¬£¬£¬ £¬£¬£¬Ëæ×ÅÄêËêµÄÔöÌí¶ø¼ÓÖØ£¬£¬£¬£¬ £¬£¬£¬»¹ÌåÏÖ³öÖеÈˮƽµÄÂѰ×Äò¡£¡£¡£¡£¡£¡£

ÊÔÑéЧ¹ûÏÔʾ£¬£¬£¬£¬ £¬£¬£¬¾­ÓÉΪÆÚ8ÖܵÄÖÎÁÆ£¬£¬£¬£¬ £¬£¬£¬Óë¿Õȱ±ÈÕÕ×édb/dbСÊóÏà±È£¬£¬£¬£¬ £¬£¬£¬MCR»·ëĸ߼ÁÁ¿×éСÊóµÄÌÇÉöÏà¹ØÖ¸±ê¾ùÓÐÏÔ×ŵĸÄÉÆ£º

1¡¢ ¶àÌǺÍÌÇÂѰ×ˮƽ£ºÏÔÖø½µµÍ×éÖ¯ÖжàÌǺÍÌÇÂѰ×ˮƽ£»£»£»£»£»ÓëÄ£×Ó×éÏà±ÈϽµ·ù¶ÈÔ¼2/3£¬£¬£¬£¬ £¬£¬£¬ÓëGLP-1¶àëÄ×éÁÆÐ§Ï൱£»£»£»£»£»

2¡¢ ½ºÔ­ÂѰ×ˮƽ£º´ó·ù¶È½µµÍ½ºÔ­ÂѰ×ˮƽ£¨Ô¼2/3£©£¬£¬£¬£¬ £¬£¬£¬ïÔÌ­½ºÔ­³Á»ý£¬£¬£¬£¬ £¬£¬£¬ÏÔÖø¸ÄÉÆÉöÔàÏËά»¯Ë®Æ½£¬£¬£¬£¬ £¬£¬£¬ÓëGLP-1¶àëÄ×éÁÆÐ§Ï൱£»£»£»£»£»

3¡¢ ÄòÂѰ×ˮƽ£ºÖÎÁÆ4Öܽ«ÄòÂѰ×ˮƽ´Ó»ùÏß½µÖÁÒ»°ë¡£¡£¡£¡£¡£¡£

 

ͼ1. db/dbСÊóÉöÔಡ±äͼ

G1¿µ½¡±ÈÕÕ×é/G2Ä£×Ó×é/G3»·ëĵͼÁÁ¿×é/ G4»·ëĸ߼ÁÁ¿×é/G5 GLP-1¶àëÄ×é

 

MCR»·ëÄ£º¶à°ÐµãЭͬÔöЧ

 

MCR»·ëÄÔÚÌÇÄò²¡Éö²¡ÖÐÌåÏÖ³öµÄ׿ԽÁÆÐ§£¬£¬£¬£¬ £¬£¬£¬Ô´ÓÚÆä×÷ΪһÖÖЭͬÐÔË«ÊÜÌ弤¶¯¼ÁµÄÆæÒìÉè¼Æ¡£¡£¡£¡£¡£¡£¸Ã·Ö×ÓʹÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ£¬£¬£¬£¬ £¬£¬£¬ÊµÏÖÁË¶ÔºÚÆ¤ÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î¡£¡£¡£¡£¡£¡£

ÕâÖÖË«ÖØ°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄЭͬÔöЧЧӦ£¬£¬£¬£¬ £¬£¬£¬ÅäºÏ×÷ÓÃÓÚÌÇÄò²¡Éö²¡µÄ½¹µã²¡Àí»·½Ú£¬£¬£¬£¬ £¬£¬£¬×îÖÕµ¼ÖÂÂѰ×Äò¼õÇá¡¢×ãϸ°û±£»£»£»£»£»¤¼°ÉöСÇòÂ˹ý¹¦Ð§¸ÄÉÆµÈ¶àά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæ×ª£¬£¬£¬£¬ £¬£¬£¬Õ¹ÏÖÁ˶à°Ðµã¸ÉÔ¤Õ½ÂÔÔÚÖØ´ó´úлÐÔ¼²²¡ÖÎÁÆÖеÄÍ»³öÓÅÊÆ¡£¡£¡£¡£¡£¡£

¼¤»îMC1R£ºÃâÒßµ÷Àí¿¹Ñ×+ÒÖÖÆÏËά»¯Àú³Ì+Ö±½Ó±£»£»£»£»£»¤×ãϸ°û

MC1RÖ÷Òª±£´æÓÚÆ¤·ôÉ«ËØÏ¸°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨°üÀ¨×ãϸ°ûºÍϵĤϸ°û£©¡£¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R£¬£¬£¬£¬ £¬£¬£¬ÏÔÖøÒÖÖÆNF-κBµÄ»î»¯£¬£¬£¬£¬ £¬£¬£¬ïÔ̭һϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ±¬·¢2 3£»£»£»£»£»Í¬Ê±Ôö½ø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄÊÍ·Å2 3£¬£¬£¬£¬ £¬£¬£¬µ÷ÀíÃâÒßϸ°û£¬£¬£¬£¬ £¬£¬£¬¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬£¬£¬£¬ £¬£¬£¬Å¤×ªÉöÔà´ÙÑ×״̬¡£¡£¡£¡£¡£¡£

ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼Ö¹¦Ð§ËðʧµÄ×îºóͨ·¡£¡£¡£¡£¡£¡£ÓÐÑо¿Åú×¢£¬£¬£¬£¬ £¬£¬£¬ºÚƤÖÊËØ¼¤¶¯¼Á±»Ö¤Êµ¿ÉÒÔÞ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩£¬£¬£¬£¬ £¬£¬£¬´Ó¶øïÔÌ­½ºÔ­ÂѰ׵Èϸ°ûÍâ»ùÖʵĺϳɣ¬£¬£¬£¬ £¬£¬£¬ÑÓ»ºÉöСÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄÀú³Ì4¡£¡£¡£¡£¡£¡£

×ãϸ°ûÊÇ×é³ÉÉöÔàÂ˹ýÆÁÕϵÄÒªº¦Ï¸°û£¬£¬£¬£¬ £¬£¬£¬ÆäËðÉ˺ÍÍÑÂäÊÇÂѰ×ÄòµÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ¡£¡£¡£¡£¡£¡£Ò»Ð©Ñо¿Ö¸³ö£¬£¬£¬£¬ £¬£¬£¬ºÚƤÖÊËØ¼¤¶¯¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£©£¬£¬£¬£¬ £¬£¬£¬ÎÈ¹ÌÆäϸ°û¹Ç¼Ü£¬£¬£¬£¬ £¬£¬£¬ÒÖÖÆµòÍö£¬£¬£¬£¬ £¬£¬£¬´Ó¶ø´Ó½á¹¹ÉÏά»¤Â˹ý¹¦Ð§µÄÍêÕûÐÔ£¬£¬£¬£¬ £¬£¬£¬ïÔÌ­ÂѰ×Äò5 6¡£¡£¡£¡£¡£¡£

 

ͼ2. MCRÔÚÉöÔàϸ°ûÖеÄÂþÑÜ5

 

¼¤»îMC4R£º¸ÄÉÆÒȵºËضԿ¹ºÍ´úл

 

MC4RÖ÷Òª±£´æÓÚÖÐÊàÉñ¾­ÏµÍ³£¬£¬£¬£¬ £¬£¬£¬¼ÓÈëµ÷ÀíÄÜÁ¿Æ½ºâºÍʳÓû¡£¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC4R£¬£¬£¬£¬ £¬£¬£¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл£¬£¬£¬£¬ £¬£¬£¬ÓÐÀûÓÚ´ÓȪԴÉÏÖÎÁÆÌÇÄò²¡Éö²¡——ÌÇÄò²¡¡£¡£¡£¡£¡£¡£

 

MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÓ¦ÓÿÉÄÜÐÔ

 

Õ¹ÍûδÀ´£¬£¬£¬£¬ £¬£¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú½«ÒÔMCR»·ëÄÔÚ¼õÖØ´úлÁìÓòÈ¡µÃµÄÍ»ÆÆÎª»ùʯ£¬£¬£¬£¬ £¬£¬£¬ÒÀ¸½Æä×÷ÓûúÖÆµÄ½¹µãÓÅÊÆ£¬£¬£¬£¬ £¬£¬£¬Æð¾¢ÍØÕ¹ÖÐÊàÉñ¾­ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦ÖØ´óµÄÐÂ˳Ӧ֢ÁìÓò¡£¡£¡£¡£¡£¡£

 

Êг¡Ô¶¾°ÓëÕ½ÂԽṹ

 

È«ÇòÌÇÄò²¡Éö²¡ÖÎÁÆÒ©ÎïÊг¡Õý´¦ÓÚ¿ìËÙÔöÌí½×¶Î£¬£¬£¬£¬ £¬£¬£¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õß»áÉú³¤ÎªÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¬£¬£¬£¬ £¬£¬£¬»¼Õß»ùÊýÖØ´ó¡£¡£¡£¡£¡£¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª£¬£¬£¬£¬ £¬£¬£¬Ô¤¼Æ2030Ä꽫Áè¼Ý300ÒÚÃÀÔª£¬£¬£¬£¬ £¬£¬£¬Ä긴ºÏÔöÌíÂÊ´ï12.5%7¡£¡£¡£¡£¡£¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò£¬£¬£¬£¬ £¬£¬£¬ÕïÁÆÂʵÄÒ»Á¬ÌáÉýʹÆä³ÉΪ×î¾ßÔöÌí»îÁ¦µÄÊг¡Ö®Ò»¡£¡£¡£¡£¡£¡£

Ö»¹ÜÏÖÓбê×¼ÁÆ·¨Ò»Ö±½ø»¯£¬£¬£¬£¬ £¬£¬£¬µ«ÉÐÎÞÄܹ»Äæ×ªÏËά»¯Àú³ÌµÄÌØÒìÐÔÒ©Îï¡£¡£¡£¡£¡£¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷ÀíÈý´ó½¹µã»·½Úͬʱ½éÈ룬£¬£¬£¬ £¬£¬£¬ÓëÏÖÓÐÁÆ·¨ÐγÉÓÅÒ컥²¹£¬£¬£¬£¬ £¬£¬£¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸ÆæÒì²î±ð»¯ÓÅÊÆ¡£¡£¡£¡£¡£¡£

ÏÖÔÚ£¬£¬£¬£¬ £¬£¬£¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƽø£¬£¬£¬£¬ £¬£¬£¬ºóÐø½«Öص㿪չϵͳµÄÁÙ´²Ç°Ò©Ð§Óë¶¾ÀíѧÑо¿£¬£¬£¬£¬ £¬£¬£¬Ïà¹Ø½¹µã»¯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ£¬£¬£¬£¬ £¬£¬£¬¹¹½¨Á˼áʵµÄÊÖÒÕ±ÚÀÝ¡£¡£¡£¡£¡£¡£ÔÚ´ËרÀû¼Ó³ÖÏ£¬£¬£¬£¬ £¬£¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú½«È«Á¦¼ÓËÙÕâÒ»²î±ð»¯¶àëÄÐÂÒ©µÄÑз¢Àú³Ì£¬£¬£¬£¬ £¬£¬£¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´²£¬£¬£¬£¬ £¬£¬£¬Ô츣ȫÇò»¼Õߣ¬£¬£¬£¬ £¬£¬£¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½ÂԸߵء£¡£¡£¡£¡£¡£

 

 

×ÊÁÏȪԴ

1.Öйú¹«ÖÚ¿µ½¡Íø£¨2014£©£¬£¬£¬£¬ £¬£¬£¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html

2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683

3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815

4. ÕŽõ.ºÚƤÖÊËØ¶Ô¾ÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯Ö¢µÄÖÎÁÆ×÷Óü°»úÖÆÑо¿[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx

5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236

6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf

7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËÓªÌ¬ÊÆÓëͶ×ÊÔ¶¾°ÊÓ²ìÑо¿±¨¸æ.https://max.book118.com/html/2025/1022/8123135105010001.shtm

Ïà¹ØÍÆ¼ö